… , is the use of the dual bronchodilation, which is a treatment that … (LAMA) with a long-acting
β 2 -agonist (LABA), rather than a … with dual bronchodilation when they are already taking a β-…

… the role of triple therapy containing a long-acting β-agonist (LABA), a long-acting muscarinic
… population, supporting the role of dual bronchodilation therapy for the treatment of COPD. …

… of the effectiveness of β2-AR agonists [48]. We were … β-AR blockers and dual bronchodilators
also because there is experimental evidence that the co-administration of a β2-AR agonist …

… greater loss of β 2 -ARs than low efficacy agonists, or partial agonists, such as … of β 2 -ARs,
ie, they induce the same maximal response occupying fewer β 2 -ARs than partial agonists to …

Introduction Inhaled β-agonists have been foundational medications for maintenance
COPD management for decades. Through activation of cyclic adenosine monophosphate …

… Long-acting muscarinic antagonist/long-acting β 2 -agonist (LAMA/LABA, also known as
dual bronchodilator) and inhaled corticosteroid/LABA (ICS/LABA) are the cornerstone of …

… safety of fixed dual long-acting bronchodilators for chronic … dual bronchodilator agents in
patients with COPD. Patients with diagnosed COPD and treated with a long-acting beta-agonist (…

… therapy compared with long-acting β-agonist/long-acting muscarinic antagonist dual therapy
or monotherapy with a single long-acting bronchodilator in patients with stable COPD who …

… or long-acting β 2 -agonist. However, many patients receiving mono-… dual bronchodilation
has greater and consistent efficacy for lung function and symptoms than mono-bronchodilation…

… Dual therapy using long-acting muscarinic antagonists (LAMAs) and long-acting β 2 -agonists
(LABAs) in one inhaler produces superior bronchodilation to monotherapy with either …